舌下与阴道米索前列醇联合Foley导管用于足月促宫颈成熟:BEGIN随机对照试验
BEGIN试验为随机对照试验,纳入215例≥37周单胎需促宫颈成熟引产孕妇,比较舌下与阴道米索前列醇(均为25μg)联合Foley导管。阴道组中位分娩时间19.7小时,短于舌下组24.1小时(P<.001);24小时内分娩率65% vs 49%(P=.02);剖宫产率无差异。结论:联合引产时阴道途径优于舌下途径。
要点
- 阴道组24小时内分娩率更高(65% vs 49%),剖宫产率无差异。
- 联合药物与机械引产时,应优先选择阴道途径给予米索前列醇。
核心结论
- 阴道给予米索前列醇联合Foley导管引产优于舌下给予米索前列醇联合Foley导管。
- 阴道途径使更早分娩的概率约为舌下途径的2倍,且剖宫产率无差异。
- 在联合药物与机械引产时,应优先选择阴道途径给予米索前列醇。
研究设计与样本
- BEGIN试验为经机构审查委员会批准的随机对照试验,于2019年6月至2020年1月开展。
- 比较相同剂量(25μg)舌下米索前列醇与阴道米索前列醇联合Foley导管引产,按产次分层随机。
- 纳入≥37周单胎、需促宫颈成熟的行引产者;计划样本量216例以检测分娩时间缩短4小时。
主要发现
- 共215例随机分组:舌下组108例,阴道组107例。
- 阴道组中位分娩时间19.7小时,短于舌下组24.1小时(P<.001)。
- 阴道组24小时内分娩比例65%,高于舌下组49%(P=.02)。
- 两组剖宫产率无差异:阴道组17%,舌下组21%(P=.6)。
- 剔除剖宫产并校正产次后,阴道组分娩速度约为舌下组2倍(HR 2.13;95%CI 1.44-3.17)。
关键数值与推荐
- 米索前列醇剂量:舌下与阴道均为25μg,联合Foley导管。
- 主要结局为分娩时间;阴道组中位19.7小时 vs 舌下组24.1小时(P<.001)。
- 24小时内分娩率:阴道组65% vs 舌下组49%(P=.02)。
- 剖宫产率:阴道组17% vs 舌下组21%(P=.6)。
- 校正后分娩速度HR 2.13(95%CI 1.44-3.17)。
临床怎么用
- 对≥37周单胎需促宫颈成熟且计划联合药物与机械引产者,优先选择阴道途径给予米索前列醇25μg。
- 舌下途径可作为替代,但需告知分娩时间可能延长、24小时内分娩概率较低。
- 两种途径剖宫产率与母儿结局无显著差异,选择时可结合患者偏好与耐受性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Combining pharmacologic agents with mechanical ripening achieves the shortest time to labor; however, there is no clear evidence on route of drug administration. Buccal administration of misoprostol has shown greater patient acceptance but remains understudied. OBJECTIVE: This study aimed to evaluate the difference in time to delivery between buccal and vaginal administration of misoprostol along with a Foley catheter for induction of labor. STUDY DESIGN: The BEGIN trial (buccal vs vaginal misoprostol combined with Foley catheter for cervical ripening at term) was an institutional review board-approved, randomized clinical trial conducted from June 2019 to January 2020 comparing identical doses (25 μg) of buccal misoprostol and vaginal misoprostol along with a Foley catheter for induction of labor. Randomization was stratified by parity. Labor management was standardized among participants. Individuals undergoing induction of labor at ≥37 weeks with a singleton gestation and needing cervical ripening were included. Our primary outcome was time to delivery. Kruskal-Wallis, Pearson chi-squared, and Cox survival analyses with intent-to-treat principles were performed. A sample size of 216 was planned to detect a 4-hour reduction in delivery time. RESULTS: A total of 215 women (108 in the buccal drug administration group and 107 in the vaginal drug administration group) were randomized. The vaginal route of drug administration achieved a faster median time to delivery than the buccal route of drug administration (19.7 hours in the vaginal route vs 24.1 hours in the buccal route; P<.001). A greater percentage of women in the vaginal drug administration group delivered within 24 hours compared with the buccal drug administration group (65% vs 49%; P=.02). There was no difference in the cesarean delivery rate between the 2 groups (17% in the vaginal drug administration group vs 21% in the buccal drug administration group; P=.6). Individuals who received vaginal misoprostol with Foley catheter delivered 2 times faster than women who received buccal misoprostol with Foley catheter after censoring for cesarean delivery and adjusting for parity (hazard ratio, 2.13; 95% confidence interval, 1.44-3.17). There was no significant difference in maternal and neonatal outcomes. CONCLUSION: We found that vaginal administration of misoprostol was superior to buccal administration of misoprostol along with a Foley catheter for induction of labor. Furthermore, vaginal administration of misoprostol resulted in twice the chance of delivering earlier compared with buccal administration of misoprostol with no difference in cesarean delivery rates. Therefore, the vaginal route of administration of misoprostol should be preferred among individuals undergoing a combined pharmacologic and mechanical induction.
引用
- Gomez HB, Hoffman MK, Caplan R, et al. Buccal vs vaginal misoprostol combined with Foley catheter for cervical ripening at term (the BEGIN trial): a randomized controlled trial. Am J Obstet Gynecol. 2021. PMID: 33617796. doi:10.1016/j.ajog.2021.02.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。